New stock news | Gao Guang Pharmaceuticals submits application to the Hong Kong Stock Exchange

According to the app of China Fortune Finance, as disclosed by the Hong Kong Stock Exchange on December 4, Hangzhou Gaoguang Pharmaceutical Co., Ltd. (hereinafter referred to as Gaoguang Pharmaceutical) submitted an application to the main board of the Hong Kong Stock Exchange, with China International Capital Corporation and CMB International as its joint sponsors. According to the prospectus, Gaoguang Pharmaceutical is committed to exploring and developing safe and effective therapies for global autoimmune/inflammatory disease patients, and has established a unique advantage in the challenging field of neuroinflammation with world-class candidate drugs for the treatment of Alzheimer's disease and Parkinson's disease. With end-to-end internal capabilities from target selection, candidate drug discovery to clinical development, the company has built a differentiated asset portfolio (covering a variety of autoimmune diseases and neurodegenerative disease indications), including four candidates in clinical stage and multiple candidates in pre-clinical stage.